Journal Watch · Journal of Controlled Release · 2026

Biomineralized nanoemulsion delivers mRNA for potent cancer immunotherapy.

These findings demonstrated that MnNE represented a safe and effective mRNA vaccine platform with substantial potential for cancer immunotherapy.

Xu Y, Tang X, Guo Z et al.Journal of Controlled Release3 min readPharma relevance 70/100

DOI: 10.1016/j.jconrel.2026.114889PMID: 41933800Study type: research study

TL;DR

These findings demonstrated that MnNE represented a safe and effective mRNA vaccine platform with substantial potential for cancer immunotherapy.

Key findings

  • Using ovalbumin (OVA) as a model antigen, MnNE-mOVA elicited strong antigen-specific humoral and cellular immune responses.
  • In both prophylactic and therapeutic E.G7-OVA tumor models, MnNE-mOVA significantly suppressed tumor growth and prolonged the survival compared with LNP-based formulations.
  • Also, among all treatment groups, MnNE-mOVA most effectively reversed the immunosuppressive tumor microenvironment.
  • These findings demonstrated that MnNE represented a safe and effective mRNA vaccine platform with substantial potential for cancer immunotherapy.

What they did

To address these concerns, we developed a PEG-free nanoemulsion (NE) platform to deliver mRNA and minimize hepatic accumulation. We further employed a biomineralization strategy to anchor Mn<sup>2+</sup> onto human serum albumin (HSA), thereby mitigating the cytotoxicity of free Mn<sup>2+</sup> and forming a manganese-modified nanoemulsion (MnNE), which effectively activates the STING pathway. Compared with the LNP formulation of Moderna, MnNE showed superior transfection efficiency in antigen-presenting cells (APCs) following intramuscular injection.

Full abstract (original)

Background: mRNA vaccines show great promise in cancer immunotherapy by eliciting potent cellular immune responses. Lipid nanoparticles (LNPs), validated through widespread use in COVID-19 vaccination, have become the most widely studied platform. However, their reliance on PEGylated lipids and tendency for hepatic accumulation may pose limitations for broader applications.

What they did: To address these concerns, we developed a PEG-free nanoemulsion (NE) platform to deliver mRNA and minimize hepatic accumulation. We further employed a biomineralization strategy to anchor Mn<sup>2+</sup> onto human serum albumin (HSA), thereby mitigating the cytotoxicity of free Mn<sup>2+</sup> and forming a manganese-modified nanoemulsion (MnNE), which effectively activates the STING pathway. Compared with the LNP formulation of Moderna, MnNE showed superior transfection efficiency in antigen-presenting cells (APCs) following intramuscular injection.

Results & conclusions: Using ovalbumin (OVA) as a model antigen, MnNE-mOVA elicited strong antigen-specific humoral and cellular immune responses. In both prophylactic and therapeutic E.G7-OVA tumor models, MnNE-mOVA significantly suppressed tumor growth and prolonged the survival compared with LNP-based formulations. Also, among all treatment groups, MnNE-mOVA most effectively reversed the immunosuppressive tumor microenvironment. These findings demonstrated that MnNE represented a safe and effective mRNA vaccine platform with substantial potential for cancer immunotherapy.

Abstract © the authors / Journal of Controlled Release (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.jconrel.2026.114889 · PubMed 41933800.

Why it matters for pharma & biotech

  • Directly relevant to teams in mRNA / delivery technology, vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: mRNA / delivery technology · vaccines

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Controlled Release study find?

These findings demonstrated that MnNE represented a safe and effective mRNA vaccine platform with substantial potential for cancer immunotherapy.

What type of study is this?

It is a research study, published in Journal of Controlled Release in 2026. To address these concerns, we developed a PEG-free nanoemulsion (NE) platform to deliver mRNA and minimize hepatic accumulation.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.jconrel.2026.114889. PubMed ID: 41933800. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Xu Y, Tang X, Guo Z et al.. Biomineralized nanoemulsion delivers mRNA for potent cancer immunotherapy.. Journal of Controlled Release (2026). DOI: 10.1016/j.jconrel.2026.114889.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/biomineralized-nanoemulsion-delivers-mrna-for-potent-cancer-immunotherap-114889/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides